A multicenter, prospective randomized controlled study on the effects of dapagliflozin on peritoneal and residual kidney function in peritoneal dialysis patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400088818

Enrollment

Unknown

Registered

2024-08-27

Start date

2024-08-28

Completion date

Unknown

Last updated

2024-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peritoneal dialysis

Interventions

Dapagliflozin:Dapagliflozin oral 10mg daily for 12 months.

Control group:None

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Age = 18 years old. (2) Patients with PD duration = 3 months. (3) Patients with regular follow-up . (4) Patients who voluntarily participate in this study and sign informed consent forms.

Exclusion criteria

Exclusion criteria: (1) Patients with type 1 diabetes mellitus. (2) Patients who developed peritonitis within 3 months. (3) Currently receiving SGLT2i treatment or within the past 3 months. (4) Patients with abnormal liver function, including ALT or AST > 3 times the upper limit of normal, or total bilirubin>2 times the upper limit of normal. (5) Recurrent severe hypoglycemia ( more than two episodes during one month). (6) History of diabetes ketoacidosis. (7) Allergic to dapagliflozin. (8) Combined symptomatic urinary tract infections. (9) Patients with combined tumors and severe cachexia. (10) Pregnancy or women who are breast-feeding.

Design outcomes

Primary

Measure	Time frame
Ultrafiltration volume;	—

Secondary

Measure	Time frame
Residual renal function;Dialysate glucose;	—

Countries

China

Contacts

Public ContactChen Kehong

Army Medical Center of PLA

chenkehong@foxmail.com+86 23 6875 7729

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026